Navigation Links
China Medicine Announces Stock Repurchase Plan
Date:7/9/2010

GUANGZHOU, China, July 9 /PRNewswire-Asia/ -- China Medicine Corporation (OTC Bulletin Board: CHME) ("China Medicine" or "the Company"), a leading manufacturer, developer and distributor of Western pharmaceuticals, traditional Chinese medicines ("TCM"), and other health products, today announced that its board of directors authorized a stock repurchase program. The program authorizes a buyback of the Company's common stock up to a value of $2.0 million. The authorization is valid through July, 2011. The program utilizes funds currently held in the escrow account pursuant to the Company's agreement with its principal shareholder, OEP CHME Holdings, LLC, an affiliate of One Equity Partners, the private equity arm of JP Morgan, dated January 28, 2010.

Mr. Senshan Yang, Chairman and CEO of China Medicine Corporation stated, "We have the fundamental strength to pursue a variety of opportunities with our cash, and today's authorization is an appropriate and strategic decision that brings us additional flexibility to leverage our strong balance sheet. We are committed to enhancing shareholder value, and we have confidence in our long-term growth plan to expand the Company's product portfolio and geographical footprint in China."

China Medicine may (but is not obligated to) repurchase shares of its common stock from time to time on the open market or in privately negotiated transactions pursuant to Rule 10b-5, Rule 10b5-1, Rule 10b-18 and other applicable legal requirements of the SEC. The timing and actual number of shares repurchased will depend on a variety of factors including regulatory restrictions on price, manner, timing, and volume, corporate and other regulatory requirements and other market conditions in an effort to minimize the impact of the purchases on the market for the stock. The repurchased stock will be cancelled and returned to the Company's authorized but unissued Common Stock to be used for acquisitions and other valid corporate purposes.

About China Medicine Corporation

China Medicine Corporation, a comprehensive enterprise with a research and development centre, manufacturing facilities and well established sales network, engages in the production and distribution of prescription and over the counter ("OTC") drugs, traditional Chinese medicine products, herbs and dietary-supplements, medical devices, and medical formulations in China. The Company distributes its products to wholesale distributors, including more than 300 hospitals and 500 medicine companies that sell to over 2,000 drug stores in 28 provinces throughout China. The Company is developing a number of proprietary products for a variety of uses, including oncology, high blood pressure and the removal of toxins from food and animal feeds. For more information, please visit the Company's website at http://www.cmc621.com .

Safe-Harbor Statement

This press release contains forward-looking statements concerning the Company's business and products. The Company's actual results may differ materially depending on a number of risk factors including, but not limited to, the following: general economic and business conditions, obtaining regulatory approval for new products, government support for rural health care, competition from existing and new competitors, changes in technology, and various other factors beyond its control. All forward-looking statements are expressly qualified in their entirety by this Cautionary Statement and the risk factors detailed in the Company's reports filed with the Securities and Exchange Commission. China Medicine Corporation undertakes no duty to revise or update any forward-looking statement to reflect events or circumstances after the date of this release.

    For more information, please contact:

    ICR, Inc.
     In New York:
     Ms. Christine Duan
     Tel: +1-203-682-8200

     In Beijing:
     Ms. Wen Lei Zheng
     Tel: +86-10-6599-7968

    China Medicine Corporation
     In Guangzhou:
     Ms. Gavin Chen
     Tel: +86-20-8737-2102


'/>"/>
SOURCE China Medicine Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
2. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
3. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
5. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
6. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
7. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
8. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
9. China Animal Welfare Law Under Review While 36,000 Dogs Culled
10. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
11. Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... 2016 Global Insulin Needles ... 09 key companies and supported with 272 tables ... study on the current state of the Insulin ... industry including definitions, classifications, applications and industry chain ... for the international market including development history, competitive ...
(Date:5/3/2016)... ACME Markets, Delaware County ... Councilman Dave White announced today the availability ... pharmacies across Delaware County . According ... has saved 26,463 lives nationwide over the past 20 years. Since ... were authorized to administer naloxone to overdose victims, 244 lives ...
(Date:5/3/2016)... DUBLIN , May 3, 2016 ... to pay $55 million to a woman who says ... State court awarded Gloria Ristesund $5 million ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... of accusations against the company. In February, the same ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... , ... Dr. Benjamin Stong of Kalos Facial Plastic Surgery, LLC in Atlanta, ... double board certified and the only facial plastic surgeon in Atlanta to offer ... such as stem cells can be used to provide stabilization to hair transplant results ...
(Date:5/5/2016)... ... , ... Talent Tech Labs (TTL) is pleased to announce its ... Nurses Week (May 6-12). Currently, HireNurses is a job listing and matching platform ... Tech Lab Virtual Incubation program, they will dramatically expand the functionality and ease of ...
(Date:5/5/2016)... ... May 05, 2016 , ... VisualDx announced today ... VisualDx is the first point of care diagnostic support system to be widely ... system speeds diagnosis, therapy decisions and patient education for emergency physicians, hospitalists and ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... pleased to announce its new referral program, giving participants incentive for spreading the ... tight-knit community, and we know many professionals share resources with their friends and ...
(Date:5/5/2016)... ... May 05, 2016 , ... Liposuction specialist Marcia V. Byrd, MD spoke last ... at the Marriot St. Louis Airport Hotel. This year’s conference was titled “Living with ... about her unique specialization in treating Lipedema. Dr. Byrd is considered one of the ...
Breaking Medicine News(10 mins):